JWA
PTCT icon

JFS Wealth Advisors’s PTC Therapeutics PTCT Stock Holding History

JFS Wealth Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87K Buy
72
+15
+26% +$1.08K ﹤0.01% 1224
2026
Q1 		$3.88K Sell
57
-1
-2% -$71 ﹤0.01% 1280
2025
Q4 		$4.41K Buy
58
+19
+49% +$1.38K ﹤0.01% 1293
2025
Q3 		$2.39K Hold
39
– – ﹤0.01% 1397
2025
Q2 		$1.91K Sell
39
-2
-5% -$95 ﹤0.01% 1403
2025
Q1 		$2.09K Buy
41
+9
+28% +$449 ﹤0.01% 1453
2024
Q4 		$1.45K Buy
32
+6
+23% +$257 ﹤0.01% 1593
2024
Q3 		$965 Buy
26
+13
+100% +$435 ﹤0.01% 1704
2024
Q2 		$398 Hold
13
– – ﹤0.01% 1831
2024
Q1 		$379 Buy
13
+4
+44% +$112 ﹤0.01% 1833
2023
Q4 		$249 Sell
9
-7
-44% -$160 ﹤0.01% 1884
2023
Q3 		$359 Buy
16
+3
+23% +$112 ﹤0.01% 1790
2023
Q2 		$529 Buy
13
+2
+18% +$98 ﹤0.01% 1745
2023
Q1 		$533 Buy
11
+4
+57% +$183 ﹤0.01% 1714
2022
Q4 		$267 Buy
7
+1
+17% +$42 ﹤0.01% 1813
2022
Q3 		$0 Buy
+6
New +$294 ﹤0.01% 1887

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

JFS Wealth Advisors's PTCT Position: Q2 2026 in Review

JFS Wealth Advisors increased its PTC Therapeutics (PTCT) stake by 26% in Q2 2026, buying an estimated $1.08K and bringing the position to 72 shares worth $5.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

JFS Wealth Advisors first reported a position in PTCT in Q3 2022 and has held it in 16 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • JFS Wealth Advisors held 72 shares of PTC Therapeutics worth $5.87K as of Q2 2026.
  • JFS Wealth Advisors bought 15 PTC Therapeutics shares in Q2 2026, an estimated $1.08K.
  • PTC Therapeutics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1224 holding.
  • JFS Wealth Advisors first reported a position in PTC Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.